Lidocaine (Caloject, Dobisim)
Lidocaine
Hetero Drugs South Africa (Pty) Ltd
Registration
- Applicant
- Hetero Drugs South Africa (Pty) Ltd
- Registrations
- 6
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Caloject 20 EACH 2,0 ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE 20,0 mg | 20 | 53016153/4/0161 | Registered | Not determined | None |
| Caloject 50 EACH 5,0 ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE 50,0 mg | 50 | 53016253/4/0162 | Registered | Not determined | None |
| Caloject 300 EACH 30,0 ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE 300,0 mg | 300 | 53016353/4/163 | Registered | Not determined | None |
| Dobisim 20 EACH 2,0 ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE 20,0 mg | 20 | 530164.16153/4/0164.161 | Registered | Not determined | None |
| Dobisim 50 EACH 5,0 ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE 50,0 mg | 50 | 530165.16253/4/0165.162 | Registered | Not determined | None |
| Dobisim 300 EACH 30,0 ml SOLUTION CONTAINS LIDOCAINE HYDROCHLORIDE 300,0 mg | 300 | 530166.16353/4/166.163 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Lidocaine
- when intended for ophthalmic or parenteral use;
- when intended for the treatment of neuropathic pain associated with previous herpes zoster infection;
- except when intended for topical use; (S1)
- except in oral preparations containing 2 percent or less of lidocaine per dosage form. (S1)
Consolidated Schedules 06 July 2026, lines 6923 to 6935
S1: Lidocaine
- when intended for topical use;
- in oral preparations containing 2 percent or less of lidocaine, per dosage unit;
- except when intended for ophthalmic or parenteral use; (S4)
- except when intended for the treatment of neuropathic pain associated with previous herpes zoster infection. (S4)
Consolidated Schedules 06 July 2026, lines 777 to 786
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
Drag to rotate. Structure from PubChem CID 3676.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.